Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-27T15:57:05.385Z Has data issue: false hasContentIssue false
  • English
  • Français

Panic in Australia

Published online by Cambridge University Press:  16 April 2020

GD Burrows ,
TR Norman ,
SR Ellen ,
KP Maguire  and
FK Judd
GD Burrows
Affiliation:
Department of Psychiatry, University of Melbourne, Austin and Repatriation Medical Centre, HeidelbergVictoria, 3084, Australia
TR Norman
Affiliation:
Department of Psychiatry, University of Melbourne, Austin and Repatriation Medical Centre, HeidelbergVictoria, 3084, Australia
SR Ellen
Affiliation:
Department of Psychiatry, University of Melbourne, Austin and Repatriation Medical Centre, HeidelbergVictoria, 3084, Australia
KP Maguire
Affiliation:
Department of Psychiatry, University of Melbourne, Austin and Repatriation Medical Centre, HeidelbergVictoria, 3084, Australia
FK Judd
Affiliation:
Department of Psychiatry, University of Melbourne, Austin and Repatriation Medical Centre, HeidelbergVictoria, 3084, Australia
Get access

Summary

Panic disorder is widespread in Australia, often in combination with other psychiatric conditions such as agoraphobia or major depression. Pharmacotherapy for panic disorder in Australia commenced with benzodiazepines, and later progressed to tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). More recently, treatment has moved towards use of the selective serotonin reuptake inhibitors (SSRIs), which are effective and better tolerated. Paroxetine is the first drug of this class to receive approval for treatment of panic disorder in Australia.

Keywords

panic disorderselective serotonin reuptake inhibitorstricyclic antidepressantsbenzodiazepines
Type
Research Article
Information
European Psychiatry , Volume 13 , Issue S2 , 1998 , pp. 71s - 74s
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldwin, JDepression and panic: co-morbidity Eur Psychiatry 13suppl 21998 65s–70sCrossRefGoogle Scholar
Ballenger, JC, Burrows, GD, DuPont, RLet alAlprazolam in panic disorder and agoraphobia: results from a multicentre trial. I. Efficacy in short-term treatment Arch Gen Psychiatry 45 1988 413–422CrossRefGoogle ScholarPubMed
Ballenger, JCNew treatments for panic Eur Psychiatry 13suppl 21998 75s–81sCrossRefGoogle ScholarPubMed
Ballenger, JCPanic disorder: efficacy of current treatments Psychopharmacol Bull 29 1993 477–486Google ScholarPubMed
Breier, R, Charney, S, Heninger, GMajor depression in patients with agoraphobia and panic disorder Arch Gen Psychiatry 41 1984 1129–1135CrossRefGoogle ScholarPubMed
Burrows, GD, Judd, FK, Norman, TRLong-term treatment of panic disorder J Psychiatry Res 27suppl 11993 111–125CrossRefGoogle ScholarPubMed
Cassano, GB, Petracca, A, Perugi, G, Nisita, C, Musetti, LClomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine J Affect Disord 14 1988 123–127CrossRefGoogle ScholarPubMed
Cross National Collaborative Panic Study, Second Phase Investigators Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine and placebo Br J Psychiatry 160 1992 191–202CrossRefGoogle Scholar
Dunbar, GC, Judge, RLong-term evaluation of paroxetine, clomipramine and placebo in panic disorder Eur Neuropsychopharmacol 5 1995 361Google Scholar
Eaton, WW, Kessler, RC, Wittchen, HU, Magee, WJPanic and panic disorder in the United States Am JPsychiatry 151 1994 413–420Google ScholarPubMed
Fontaine, R, Chouinard, GAntipanic effect of clonazepam Am J Psychiatry 141 1984 149Google ScholarPubMed
Judd, FK, Burrows, GD, Marriott, PF, Norman, TRA short term open clinical trial of clobazam in the treatment of patients with panic attacks Int Clin Psychopharmacol 4 1989 285–293CrossRefGoogle Scholar
Judge, R, Dunbar, GCParoxetine, clomipramine and placebo in the treatment of panic disorder Eur Neuropsychopharmacol 5 1995 361CrossRefGoogle Scholar
Malizia, AL, Gunn, RN, Wilson, SJet alBenzodiazepine site pharmacokinetic/pharmacodynamic quantitation in man-direct measurement of drug occupancy and effects on the human brain in vivo Neuropharmacol 35 1996 1483–1491CrossRefGoogle Scholar
McTavish, D, Benfield, PClomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder Drugs 39 1990 136–153CrossRefGoogle Scholar
Noyes, R, Burrows, GD, Reich, JHet alDiazepam versus alprazolam for treatment of panic disorder J Clin Psychiatry 57 1996 349–355Google ScholarPubMed
Weissman, MMAnxiety disorders: an epidemiologic perspectiveRoth, M, Noyers, R, Burrows, GDHandbook of Anxiety Vol 1: Biological, Clinical and Cultural Perspectives. 1988 Elsevier Science Publishers BV OxfordGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.